The field of respiratory pharmacology & therapeutics is undergoing rapid transformation through precision medicine, novel delivery platforms, and molecular innovation. The development of dual and triple inhaler combinations, biologics targeting eosinophilic inflammation, and kinase inhibitors for fibrotic lung diseases is changing clinical paradigms. Drug response heterogeneity is now being addressed using pharmacogenomic profiling and phenotype-based treatment algorithms. Respiratory Pharmacology & Therapeutics also encompasses advances in aerosol science, including smart inhaler devices with dose tracking and feedback systems to improve adherence. As new therapeutic targets are identified through omics-based research, regulatory bodies are adapting frameworks to support accelerated approval pathways. Inhalation toxicology and drug-device compatibility are emerging concerns as personalized therapies become more complex. A collaborative ecosystem between pharmacologists, respiratory clinicians, and biotech innovators is vital to translate discovery into effective, patient-centric care.
Title : Screening questionnaires for obstructive sleep apnea: An updated systematic review
Behzad Rahmati, Isfahan University of Medical Sciences, Iran (Islamic Republic of)
Title : Improving covid 19 candidate vaccine response through probiotics and micronutrient supplementation: Evaluating the role of TLR5
Zohre Eftekhari, Biotechnology Research Center, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Novel signaling mechanisms and innovative therapeutic strategies of pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : Iatrogenic pneumothorax following nephrectomy: Case report
Chaimae Tahiri, National University Hospital Center of Fann, Senegal
Title : Towards the experience and view of personalized and precision pulmonology: An option for clinicians, geneticists and caregivers to realize the potential of genomics informed lung cancer care to secure the individualized human biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Opioid induced hypoventilation and sleep related hypoxemia in a patient on buprenorphine naloxone an underrecognized problem.
Anusha Devarajan, University of Vermont Medical Center, United States